The Fujirebio Neuro Center of Excellence has been founded with the objective of rising to this challenge.
The Neuro Center of Excellence is a research and development hub focused on the development of diagnostic solutions to these debilitating diseases. It is intended as a meeting point to share knowledge between Fujirebio and neuroscience professionals worldwide.
More than this, it is a catalyst for collaborations and partnerships between a broad range of stakeholders, including routine laboratories, contract development & manufacturing organization (CDMOs), pharmaceutical companies, clinicians, researchers, and academia.
Above all, it is a ray of hope for patients, families and caregivers.
Video: A Day At The Fujirebio Neuro Center of Excellence
But why Fujirebio and why now?
Through its acquisition of Innogenetics, Fujirebio has an unrivalled heritage as a pioneer in the field of Alzheimer’s research. Today laboratories across the world depend on its ground-breaking biomarkers and automated testing systems.
With the additional acquisition of neurodegenerative disease biomarker pioneers at ADx NeuroSciences in 2022, Fujirebio combines an additional biomarker portfolio and unique know-how with its own solid experience in high quality IVD products and its strategic CDMO partnerships that make unique testing solutions available to the entire diagnostics industry.
Key Milestones In The Company's Involvement With Alzheimer's
- The launch in 1995 of the world’s first commercialized biomarker for early detection of the plaques associated with Alzheimer’s on the INNOTEST® platform
- The launch in 2005 of plasma-based biomarkers on the INNO-BIA platform
- The ability to perform, in 2018 and for the first time ever, the four most important neurodegeneration parameters on a single fully automated CLEIA platform (LUMIPULSE® G)
- The availability, in 2022, of the plasma assays pTau 181, β-Amyloid 1-42 and β-Amyloid 1-40 on the LUMIPULSE G platform
- Most recently, the FDA-authorization of our Lumipulse G β-Amyloid Ratio (1-42/1-40) test, as the first ever, for marketing as an IVD test for early detection of amyloid plaques associated with Alzheimer’s disease in the USA.
The commitment to tackle neurodegenerative diseases runs deep at Fujirebio.
The profound knowledge of the diseases supports our progress to deliver promising new testing techniques, such as plasma-based tests.
Its doors are open to all participants in the race to find the next generation of diagnostics and therapeutics. This is a center for partnership and collaboration, a place for research, development and manufacture, a meeting place for brilliant minds and a starting point for great ideas.
Browse our resources dedicated to Alzheimer's disease testing
Our Doors Are Open - Contact Us
We encourage partnerships dedicated to advancing neurodegeneration diagnostics.
